Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acute Myeloid Leukemia.

Literature DB >> 26376137

Acute Myeloid Leukemia.

Hartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26376137 DOI： 10.1056/NEJMra1406184

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

966 in total

1. Ribosome engineering and fermentation optimization leads to overproduction of tiancimycin A, a new enediyne natural product from Streptomyces sp. CB03234.

Authors: Ling Liu; Jian Pan; Zilong Wang; Xiaohui Yan; Dong Yang; Xiangcheng Zhu; Ben Shen; Yanwen Duan; Yong Huang
Journal: J Ind Microbiol Biotechnol Date: 2018-02-02 Impact factor: 3.346

2. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors: Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808

3. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.

Authors: Andrew S Moore; Amir Faisal; Grace W Y Mak; Farideh Miraki-Moud; Vassilios Bavetsias; Melanie Valenti; Gary Box; Albert Hallsworth; Alexis de Haven Brandon; Cristina P R Xavier; Randal Stronge; Andrew D J Pearson; Julian Blagg; Florence I Raynaud; Rajesh Chopra; Suzanne A Eccles; David C Taussig; Spiros Linardopoulos
Journal: Blood Adv Date: 2020-04-14

4. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Authors: Brittany Knick Ragon; Olatoyosi Odenike; Maria R Baer; Wendy Stock; Gautam Borthakur; Keyur Patel; Lina Han; Helen Chen; Helen Ma; Loren Joseph; Yang Zhao; Keith Baggerly; Marina Konopleva; Nitin Jain
Journal: Clin Lymphoma Myeloma Leuk Date: 2019-03-26

5. Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.

Authors: Adrian Krygier; Dagmara Szmajda; Marta Żebrowska; Agnieszka Jeleń; Ewa Balcerczak
Journal: Oncol Lett Date: 2018-03-01 Impact factor: 2.967

Acute Myeloid Leukemia.

1. Ribosome engineering and fermentation optimization leads to overproduction of tiancimycin A, a new enediyne natural product from Streptomyces sp. CB03234.

2. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

3. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.

4. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

5. Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.

6. Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells.

7. Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3.

8. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.

9. The Potentials and Pitfalls of Using Adult Stem Cells in Cancer Treatment.

Review 10. New strategies to treat AML: novel insights into AML survival pathways and combination therapies.